Clinical Trial Update: Study of Metformin Plus Paclitaxel/Carboplatin/Bevacizumab in Patients With Adenocarcinoma. [Phase 2]

View source ↗

Summary

Phase 2 trial of metformin combined with paclitaxel/carboplatin/bevacizumab in non-small cell lung cancer (lung adenocarcinoma) was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Adenocarcinoma
• Non-small Cell Lung Carcinoma

Drugs mentioned

• Bevacizumab (bevacizumab)
• CARBOPLATIN (Carboplatin)
• PACLITAXEL (PACLITAXEL)
• metformin (metformin)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: Carcinoma, Non-Small-Cell Lung, Lung Adenocarcinoma | Phase 2 | Status: TERMINATED | Results posted: 2018-12-19